Emergent BioSolutions (EBS) Change in Receivables (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Change in Receivables of $38.9 million for Q1 2026, down 46.93% year-over-year from $73.3 million in Q1 2025, and up 174.95% quarter-over-quarter from -$51.9 million in Q4 2025.
Emergent BioSolutions (EBS) Change in Receivables (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Change in Receivables history runs 17 years deep, the most recent figure standing at $38.9 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 46.93% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at -$59.9 million (down 225.58% YoY), while the FY2025 annual figure was -$25.5 million, down 204.51% from the prior year.
- Change in Receivables for Q1 2026 stood at $38.9 million, up from -$51.9 million in the prior quarter.
- The five-year high for Change in Receivables was $132.4 million in Q2 2023, with the low at -$118.5 million in Q2 2025.
- The 5-year median for Change in Receivables is -$4.0 million (2022), against an average of -$3.5 million.
- Peak annual rise in Change in Receivables reached 3410.0% in 2023, while the deepest fall reached 569.08% in 2023.
- Emergent BioSolutions' Change in Receivables stood at -$35.6 million in 2022, then declined by 3.65% to -$36.9 million in 2023, then surged by 308.94% to $77.1 million in 2024, then sank by 167.32% to -$51.9 million in 2025, then surged by 174.95% to $38.9 million in 2026.
- Business Quant data shows EBS's Change in Receivables at $38.9 million in Q1 2026, -$51.9 million in Q4 2025, and $71.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 68.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.80 Mn |
| Jun 30, 2026 | 68.80 Mn |
| Mar 31, 2026 | 38.90 Mn |
| Mar 31, 2026 | 38.90 Mn |
| Dec 31, 2025 | -51.90 Mn |
| Dec 31, 2025 | -51.90 Mn |
| Sep 30, 2025 | 71.60 Mn |
| Sep 30, 2025 | 71.60 Mn |
| Jun 30, 2025 | -118.50 Mn |
| Jun 30, 2025 | -118.50 Mn |
| Mar 31, 2025 | 73.30 Mn |
| Mar 31, 2025 | 73.30 Mn |
| Dec 31, 2024 | 77.10 Mn |
| Dec 31, 2024 | 77.10 Mn |
| Sep 30, 2024 | -82.30 Mn |
| Sep 30, 2024 | -82.30 Mn |
| Jun 30, 2024 | -20.40 Mn |
| Jun 30, 2024 | -20.40 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Mar 31, 2024 | 50.00 Mn |